Genetic and genomic alterations in the PI3K pathway were previously found in all breast cancer subtypes, with basal-like cancers having more loss of pathway inhibitors PTEN and INPP4B, and with luminal A cancers having more mutations in PIK3CA. This evidence concerns the gene INPP4B and breast carcinoma.